Serum matrix metalloproteinase-2,9 activity, galectin-3 and systemic inflammation in patients with postinfarction heart failure with preserved ejection fraction.

O. Kuryata, A. Zabida, O. Sirenko

Abstract


The available data suggest that heart failure (HF) after myocardial infarction (MI) is a very frequent event. Recent meta-analysis showed that restrictive mitral filling pattern, the most severe form of diastolic dysfunction, was presented in approximately 10% of the patients with preserved ejection fraction. In addition, restrictive pattern was associated with poor outcome. However, the true prevalence and relevance of diastolic dysfunction after MI remains to be elucidated. Objective: study was designed to evaluate the serum level of MMP-2,9, galactin-3 and C-reactive protein (C-RP) in postinfarction heart failure with preserved ejection fraction (HFpEF) patients. Methods: We divided all included patients into two main groups: 1st group – 20 patients with HFpEF and history of myocardial infarction. 2nd group – 18 patients with HFpEF and stable angina. Standard laboratory blood tests for erythrocyte sedimentation rate (ESR), C-RP, haematological parameters, lipid profile, glucose, renal and liver function tests were performed and calculated body mass index (BMI) for all patients. MMP activity assay and galectin-3 serum level was detected for all patients. Results: It was established significant differences between study groups in MMP-2, MMP-9 levels. Particularly, patients with HFpEF with MI in anamnesis had significantly higher MMP-2, MMP-9 levels on 21.8% and 20.7% respectively. The C-RP and leucocytes levels were significantly higher in 1st group pts. Significant differences in MMP-2, MMP-9 were established in 1st group patients in different age groups (p<0.05) (tab. 3). The MMP 2 level was positively correlated with MMP 9 level (R=0.73, p<0.05), the MMP 9 level – with age (R=0.68, p<0.05). There were no significant differences between galectin-3 level in study group. But we estimated significant differences in galectin-3 level between 1st and 2nd subgroups (p<0.05). Conclusion: Serum MMP-2, MMP-9, CRP and galactin-3 were significantly increased in pts with postinfarction heart failure with preserved ejection fraction compare to pts without myocardial infarction in anamnesis.

Keywords


postinfarction chronic heart failure; metalloproteinase; galectin-3

Full Text:

PDF

References


Kuryata OV, Sirenko O. [Daily Blood Pressure, lipid profile of blood in patients with arterial hypertension in combination with rheumatoid arthritis and efficacy of atorvastatin]. Simeyna medytsyna. 2015;3 (59):155-9. Ukrainian. doi: 10.22141/2224-1485.6.50.2016.89771

Kuryata OV, Zabida A, Chvora DL. [Risk factors, conditions of cardiohemodynamics and renal function in patients with chronic heart failure and myocardial in­farc­tion in anamnesis]. Medicni perspektivi. 2017;ХХІІ(3):25-32. Ukrainian. https://doi.org/10.26641/2307-0404.2017.3.111914

Kuryata AV, Lysunets TK, Noda OYu. [The ef­fectiveness of cocarina in complex therapy in patients with systemic connective tissue diseases with myocardial damage and manifestations of heart failure]. Mezhdu­narodnyy meditsinskiy zhurnal. 2012;2:44-49. Russian.

Kawamura N, Kubota T, Kawano S, et al. Bloc­kade of NF-κB improves cardiac function and survival without affecting inflammation in TNF-α-induced cardio­myopathy. Cardiovasc. Res. 2005;66:520-9.

Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehs104

Weir RA, Petrie CJ, Murphy CA, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ. Heart Fail. 2013;492-8. doi: 10.1161/CIRCHEARTFAILURE.112.000146

de Boer RA, Voors AA, Muntendam P, et al. Ga­lectin-3: a novel mediator of heart failure development and progression. European Journal of Heart Failure. 2009;11(9):811-7. doi: 10.1093/eurjhf/hfp097.

Saksida T, Nikolic I, Vujicic M, et al. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. J Cell Physiol. 2013;228:1568-76. doi: 10.1002/jcp.24318

Gheorghiade M, Fonarow GC. Management of post-myocardial infarction patients with left ventricular systolic dysfunction. Am. J. Med. 2007;120:109-20. doi: 10.1016/j.amjmed.2005.08.010

Møller JE, Whalley GA, Dini FL, et al. Inde­pendent prognostic importance of a restrictive left ven­tricular filling pattern after myocardial infarction: an individual patient me­ta-analysis: Meta-Analysis Research Group in Echocar­dio­graphy acute myocardial infarction. Circulation. 2008;117:2591-8. doi: 10.1161/CIRCULATIONAHA.107.­738625. Epub 2008 May 12.

Sundararaj KP, Samuvel DJ, Sanders JJ, et al. Interleukin-6 released from fibroblasts is essential for upregulation of matrix metalloproteinase-1 expression by u937 macrophages in coculture-crosstalking between fibroblasts and u937 macrophages exposed to high glu­cose. J. Biol. Chem. 2009;284:13714-24.

Mukherjee R, Brinsa TA, Dowdy KB, et al. Myo­cardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107(4):618-25.

Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 ran­domized trials. PLoS ONE. 2013;8(3):e58287. doi: 10.1371/journal.pone.0058287. Epub 2013 Mar 5.

Zile MR, De Santis SM, Baicu CF, et al. Plasma galectin- 3 levels in patinets with structural and clinical manifestation of hypertensive heart disease: relationship to determination of matrix composition. Circulation. 2010;122:A12433.

Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix me­talloproteinases in post-myocardial infarction remodelling. Circulation. 2003;107(22):2857-63. doi: 10.1161/01.CIR.0000068375.40887.FA

Tsai TH, Sung PH, Chang LT, et al. Value and level of galectin-3 inacute myocardial infarction patients undergoing primary percutaneous coronary intervention. J. Atheroscler. Thromb. 2012;19:1073-82.

Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β. J. Biol. Chem. 2004;279:39513-9.


GOST Style Citations


  1. Курята О.В. Добовий профіль артеріального тиску, ліпідний спектр крові у хворих на артеріальну гіпертензію в поєднанні з ревматоїдним артритом та ефективність застосування аторвастатину / О.В. Ку­рята, О.Ю. Сіренко // Сімейна медицина. – 2015. – № 3 (59). – C. 155-159. doi: 10.22141/2224-1485.6.50.2016.89771
  2. Курята О.В. Факторы риска, состояния кар­диогемодинамики и функция почек у пациентов с хронической сердечной недостаточностью и ин­фарктом миокарда в анамнезе / О. В. Курята, А. За­бида, Д. Л. Чвора // Медичні перспективи. – 2017. – Т. ХХІІ, № 3. – C. 25-32. https://doi.org/10.26641/2307-0404.2017.3.111914
  3. Курята О.В. Эффективность кокарнита в ком­плексной терапии у пациентов c системными заболе­ваниями соединительной ткани с поражением мио­карда и проявлениями сердечной недостаточности / А.В. Курята, Т.К. Лысунец, О.Ю. Нода // Междунар. мед. журнал. – 2012. – № 2. – C. 44-49.
  4. Blockade of NF-κB improves cardiac function and survival without affecting inflammation in TNF-α-induced cardiomyopathy / N. Kawamura, T. Kubota, S. Kawano [et al.] // Cardiovascular Res. – 2005. – Vol. 66. – P. 520-529.
  5. ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC / P. Po­ni­kowski [et al.] // Eur. Heart J. – 2016. – Vol. 37, N 27. – P. 2129-200. doi: 10.1093/eurheartj/ehs104
  6. Galectin-3 and cardiac function in survivors of acu­te myocardial infarction / R.A. Weir, C.J. Petrie, C.A. Mu­rphy [et al.] // Circulation Heart Failure. – 2013. – P. 492-498. doi: 10.1161/CIRCHEARTFAILU­RE.112.000146
  7. Galectin-3: a novel mediator of heart failure de­velopment and progression / R.A. de Boer, A.A. Voors, P. Muntendam [et al.] // Eur. J. Heart Fai­lure. – 2009.- Vol. 11, N 9.- P. 811-817. doi: 10.1093/eurjhf/hfp097
  8. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro / T. Sak­sida, I. Nikolic, M. Vujicic [et al.] // J. Cell Phy­sio­logy. – 2013. – Vol. 228. – P. 1568-76. doi: 10.1002/jcp.24318
  9. Gheorghiade M. Management of post-myocardial infarction patients with left ventricular systolic dysfunction / M. Gheorghiade, G. C. Fonarow // Am. J. Me­dicine. – 2007. – Vol. 120. – P. 109-120. doi: 10.1016/j.amjmed.2005.08.010
  10. Independent prognostic importance of a res­tric­tive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Ana­lysis Research Group in Echocardiography acute myo­cardial infarction / J.E. Møller, G.A. Whalley, F.L. Dini [et al.] // Circulation. – 2008. – Vol. 117. – P. 2591-2598. doi: 10.1016/j.amjmed.2005.08.010
  11. Interleukin-6 released from fibroblasts is essential for upregulation of matrix metalloproteinase-1 expression by u937 macrophages in coculture-crosstalking between fibroblasts and u937 macrophages exposed to high glucose / K. P. Sundararaj, D. J. Samuvel, J. J. Sanders, [et al.] // J. Biology Chemistry. – 2009. – Vol. 284. – P. 13714-13724.
  12. Myocardial infarct expansion and matrix metal­loproteinase inhibition / R. Mukherjee, T.A. Brinsa, K.B. Dowdy [et al.] // Circulation. – 2003. – Vol. 107, N 4. – P. 618-625.
  13. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials / G. Savarese, B. Trimarco, S. Del­le­grottaglie [et al.] // PLoS ONE.- 2013.- Vol.8, N 3. - e58287. doi: 10.1371/journal.pone.0058287, Epub 2013 Mar 5.
  14. Plasma galectin- 3 levels in patients with struc­tural and clinical manifestation of hypertensive heart disease: relationship to determination of matrix compo­sition / M.R. Zile, S.M. De Santis, C.F. Baicu [et al.] // Circulation. – 2010. – Vol. 122. – A12433.
  15. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remo­delling / E.M. Wilson, S.L. Moainie, J.M. Baskin [et al.] // Circulation. – 2003. – Vol. 107, N 22. – P. 2857-63. doi: 10.1161/01.CIR.0000068375.40887.FA
  16. Value and level of galectin-3 inacute myocardial infarction patients undergoing primary percutaneous co­ronary intervention / T.H. Tsai, P.H. Sung, L.T. Chang [et al.] // J. Atherosclerosis, Thrombosis. – 2012. – Vol. 19. – P. 1073-1082.
  17. Xie Z. Differential regulation of matrix metal­loproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin- 1β / Z. Xie, M. Singh, K. Singh // J. Biology Chemistry. – 2004. – Vol. 279. – P. 39513-39519. doi: 10.1002/jcp.24318




DOI: https://doi.org/10.26641/2307-0404.2018.1(part1).127244

Refbacks

  • There are currently no refbacks.